A trial of Incyte's Pemazyre in patients with FGFR-altered brain cancer did not meet its primary endpoint but had encouraging secondary outcomes.

The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through ...

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the ...

Bildnachweis: ITM Isotope Technologies Munich SE, VC Magazin, Pixabay. As the global demand for targeted cancer therapies ...

Parker Institute showcases breakthroughs in immunotherapy at ASCO 2025 as CEO Dr. Karen Knudsen receives prestigious honor.

Third, since the majority of malignant gliomas recur at the primary tumor site, 136,137 locoregional therapeutics may improve local control and thus improve overall outcome. The emergence of ...

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech's Fralin Biomedical Research ...

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech's Fralin Biomedical Research ...

Transwell assay showing increased invasion in SNB19 and U251 glioma cells transfected with FAM111B-overexpressing lentivirus, compared to controls. Magnification ×20 Study shows FAM111B overexpression ...

Cancer thrives by stealing nutrients. Tumors grow fast because they hijack the body’s resources—especially glucose and fatty ...